

Freedom of Information Act 2000 – Request Reference FoI/23/657
Fungal Infection Treatment

Q1. In the last 12 months, how many patients have been treated (for any condition) with the following drugs:

Cardiff and Vale University Health Board (the UHB) is unable to provide brand-specific figures except for Ambisome.

- Amphotericin B (Ambisome): 26
- Caspofungin: 91
- Isavuconazole: 8
- Posaconazole: 115
- Voriconazole: 46

Q2a. In the last 12 months, how many hospital inpatients were diagnosed with Aspergillosis (ICD10 code: B44)?

The number of individual inpatients discharged between 1 December 2022 and 30 November 2023 coded with a diagnosis of Aspergillosis (ICD10 code: B44) was 35.

Q2b. Of the above patients diagnosed with Aspergillosis in the last 12 months, how many patients were treated with the following drugs:

- Amphotericin B (Ambisome)
- Caspofungin (Cancidas)
- Isavuconazole (Cresemba)
- Posaconazole (Noxafil)
- Voriconazole (VFEND)

In completing a search for the information requested, the UHB has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual records and the UHB considers that this would exceed the limit set within Regulations for responding to a request. The UHB has therefore relied upon the section 12 exemption of the Freedom of Information Act 2000 ('Exemption where cost of compliance exceeds appropriate limit') and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within Regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the Fees Regulations for this amount of work (18 hours) is £450 for the UHB. The Fees Regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour.

Q3a. In the last 12 months, how many hospital inpatients were diagnosed with Mucormycosis (ICD10 code: B46)?

The number of individual inpatients discharged between 1 December 2022 and 30 November 2023 coded with a diagnosis of Mucormycosis (ICD10 code: B46) was 0.

Q3b. Of the above patients diagnosed with Mucormycosis in the last 12 months, how many patients were treated with the following drugs:

- Amphotericin B (Ambisome)
- Isavuconazole (Cresemba)
- Posaconazole (Noxafil)

The UHB believes the section 12 exemption to apply here and is refusing this request.